HAEBREYK

CSL Behring GmbH

Application Filed: 2023-02-02

Trademark Application Details

Status

630

Live/Pending

NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER

Research	OneLook Acronym Finder
Serial Number	97777777
Mark Drawing Code	4000: Illustration: Drawing with word(s)/letter(s)/number(s) in Block form
Domestic Representative	Scott D. Woldow
Attorney Name	Scott D. Woldow
Attorney Docket Number	034845.371

Timeline

2023-02-02	Application Filed
2023-02-07	Location: NEW APPLICATION PROCESSING
2023-02-07	Status: Live/Pending
2023-02-07	Transaction Date

Trademark Applicants & Owners

Owner:	CSL Behring GmbH
Address	Emil-von-Behring Str. 76 Marburg DE D-35041
Legal Entity Type	Limited Liability Company
Legal Entity State	DE

Documents

Click the blue "Refresh" button to load certificates, specimines, application, and other documents.

Attorney of Record

SCOTT D. WOLDOW
SMITH, GAMBRELL & RUSSELL, LLP
1055 THOMAS JEFFERSON STREET, NW
SUITE 400
WASHINGTON, DC 20007

Good, Services, and Codes

International Codes:	5
U.S. Codes:	005,006,018,044,046,051,052

Type Code	Type
GS0051	Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE; Pharmaceutical preparations, namely for the treatment of Hereditary Angioedema, HAE, respiratory diseases, acute respiratory distress syndrome, ARDS, Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; antibodies

Type Code

Type

GS0051

Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE; Pharmaceutical preparations, namely for the treatment of Hereditary Angioedema, HAE, respiratory diseases, acute respiratory distress syndrome, ARDS, Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; antibodies

Trademark Filing History

Description	Date	Event Coding
NEW APPLICATION ENTERED	2023-02-07	1 NWAP I:Incoming Correspondence
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED	2023-02-09	2 NWOS I:Incoming Correspondence
ASSIGNED TO EXAMINER	2023-11-01	3 DOCK D:Assigned to Examiner
NON-FINAL ACTION WRITTEN	2023-11-07	4 CNRT R:Renewal
NON-FINAL ACTION E-MAILED	2023-11-07	5 GNRT F:First Action
NOTIFICATION OF NON-FINAL ACTION E-MAILED	2023-11-07	6 GNRN O:Outgoing Correspondence
TEAS RESPONSE TO OFFICE ACTION RECEIVED	2024-02-05	7 TROA I:Incoming Correspondence
ASSIGNED TO LIE	2024-07-24	8 ALIE A:Allowance for Publication
CORRESPONDENCE RECEIVED IN LAW OFFICE	2024-07-24	9 CRFA I:Incoming Correspondence
TEAS/EMAIL CORRESPONDENCE ENTERED	2024-07-24	10 TEME I:Incoming Correspondence

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.